{"id":"endralazine","rwe":[{"pmid":"20191341","year":"2010","title":"Synthesis of new 4,5-3(2H)pyridazinone derivatives and their cardiotonic, hypotensive, and platelet aggregation inhibition activities.","finding":"","journal":"Archives of pharmacal research","studyType":"Clinical Study"},{"pmid":"20702335","year":"1988","title":"Use of the whole-embryo culture system in drug safety assessment?","finding":"","journal":"Toxicology in vitro : an international journal published in association with BIBRA","studyType":"Clinical Study"},{"pmid":"3609114","year":"1987","title":"Effect of food intake on plasma levels and antihypertensive response during maintenance therapy with endralazine.","finding":"","journal":"European journal of clinical pharmacology","studyType":"Clinical Study"},{"pmid":"3758143","year":"1986","title":"Evaluation of once daily endralazine in hypertension.","finding":"","journal":"European journal of clinical pharmacology","studyType":"Clinical Study"},{"pmid":"3544243","year":"1986","title":"[Endralazine monotherapy in comparison with prazosin and hydralazine in arterial hypertension].","finding":"","journal":"Sovetskaia meditsina","studyType":"Clinical Study"}],"tags":[{"label":"endralazine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Voltage-dependent L-type calcium channel subunit alpha-1C","category":"target"},{"label":"CACNA1C","category":"gene"},{"label":"C02DB03","category":"atc"},{"label":"Active","category":"status"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"miretilan","offLabel":[],"synonyms":["BQ 22708","BQ 22-708","endralazine mesilate","endralazine mesylate","endralazine","miretilan"],"timeline":[],"approvals":[],"brandName":"Miretilan","ecosystem":[{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null}],"mechanism":{"target":"Voltage-dependent L-type calcium channel subunit alpha-1C","targets":[{"gene":"CACNA1C","source":"DrugCentral","target":"Voltage-dependent L-type calcium channel subunit alpha-1C","protein":"Voltage-dependent L-type calcium channel subunit alpha-1C"}],"modality":"Small Molecule","drugClass":"endralazine","explanation":"When you have high blood pressure, your blood vessels are like narrow roads that are congested with traffic. Miretilan helps to widen these roads by blocking the calcium channels that control the flow of calcium into the muscle cells of the blood vessel walls. This allows the blood vessels to relax and widen, which helps to lower blood pressure.","oneSentence":"Miretilan works by blocking calcium channels in blood vessels, which helps to lower blood pressure.","technicalDetail":"Miretilan acts as a selective blocker of the L-type calcium channel subunit alpha-1C, which is a critical component of the voltage-dependent calcium channel in vascular smooth muscle cells. By inhibiting the influx of calcium ions, Miretilan reduces the contraction of vascular smooth muscle cells, leading to vasodilation and a subsequent decrease in blood pressure."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1008","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ENDRALAZINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:59:58.603056","biosimilars":[],"competitors":[{"drugName":"hydralazine","drugSlug":"hydralazine","fdaApproval":"1953-01-15","genericCount":44,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"endralazine","indications":{"approved":[{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"hydralazine","brandName":"hydralazine","genericName":"hydralazine","approvalYear":"1953","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"L44741F05P","CHEBI":"CHEBI:135105","INN_ID":"4288","UMLSCUI":"C0116074","ChEMBL_ID":"CHEMBL254193","KEGG_DRUG":"D08254","DRUGBANK_ID":"DB13435","PUBCHEM_CID":"47608","SECONDARY_CAS_RN":"65322-72-7","MESH_SUPPLEMENTAL_RECORD_UI":"C014926"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"5.6 hours","clearance":"13.0 mL/min/kg","bioavailability":"75%","volumeOfDistribution":"2.2 L/kg"},"publicationCount":48,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C02DB03","allCodes":["C02DB03"]},"biosimilarFilings":[],"recentPublications":[{"date":"2010 Jan","pmid":"20191341","title":"Synthesis of new 4,5-3(2H)pyridazinone derivatives and their cardiotonic, hypotensive, and platelet aggregation inhibition activities.","journal":"Archives of pharmacal research"},{"date":"1988","pmid":"20702335","title":"Use of the whole-embryo culture system in drug safety assessment?","journal":"Toxicology in vitro : an international journal published in association with BIBRA"},{"date":"1987","pmid":"3609114","title":"Effect of food intake on plasma levels and antihypertensive response during maintenance therapy with endralazine.","journal":"European journal of clinical pharmacology"},{"date":"1986","pmid":"3758143","title":"Evaluation of once daily endralazine in hypertension.","journal":"European journal of clinical pharmacology"},{"date":"1986","pmid":"3544243","title":"[Endralazine monotherapy in comparison with prazosin and hydralazine in arterial hypertension].","journal":"Sovetskaia meditsina"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Miretilan (Endralazine) is a small molecule drug that targets the voltage-dependent L-type calcium channel subunit alpha-1C. It is used to treat hypertensive disorders. The commercial status of Miretilan is unknown, and it is not FDA-approved. Key safety considerations include its half-life of 5.6 hours and bioavailability of 75%. Further information on its generic status and patent status is not available.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}